Hematocrit Test Devices Market Overview 2024-2033 - Trends, Analysis And Insights

"The new report published by The Business Research Company, titled Hematocrit Test Devices Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the hematocrit test devices market size has grown strongly in recent years. It will grow from $4.35 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $5.98 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15582&type=smp

Impact Of Blood Disorders On The Hematocrit Test Devices Market
The growing cases of blood disorders are expected to propel the growth of the hematocrit test devices market going forward. A blood disorder is a condition that affects the components of human blood, including red blood cells, white blood cells, platelets, and blood plasma. Blood disorders are becoming more common due to several variables, including genetic predispositions, pollution in the environment, and lifestyle changes. Hematocrit test devices are primarily used to measure the volume percentage of red blood cells in whole blood, providing crucial information about the patient's hematological health. For instance, in January 2024, according to a report published by the American Cancer Society, a US-based non-profit organization, approximately 62,770 new cases of leukemia, encompassing all types, are anticipated in the United States in 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, primarily affecting adults, with approximately 11,220 deaths attributed to AML, almost exclusively occurring in adult patients. Therefore, the growing cases of blood disorders are driving the growth of the hematocrit test devices market.

Innovative CBC Hematology Analyzers Revolutionize Blood Cell Analysis
Major companies operating in the hematocrit test device market are developing innovative products, such as complete blood count (CBC) hematology analyzers, to provide quantitative and qualitative information about these blood cells. A complete blood count (CBC) hematology analyzer is an automated instrument used to measure and analyze various components of blood, including red blood cells (RBCs), white blood cells (WBCs), and platelets. For instance, in March 2022, Mindray Medical International Limited, a China-based medical device company, launched the BC-700 hematology analyzer series, a complete blood count (CBC) hematology analyzer that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. The BC-700 hematology analyzer, along with its counterparts BC-720, BC-760, and BC-780, constitutes a series tailored to empower medium-volume laboratories with cutting-edge diagnostic technologies akin to those found in premium products. The BC-700 Series is a more compact version of the high-end BC-6000 Series, built on the same platform and distinguished by Mindray's SF Cube 3D analysis technology. The SF Cube technology uses fluorescence and bi-angular laser scatter signals to analyze target cells in three dimensions.

The hematocrit test devices market covered in this report is segmented -

1) By Product: Hematocrit Test Meter, Hematocrit Test Analyzer, Reagents And Consumables
2) By Application: Anemia, Polycythemia Vera, Congenital Heart Diseases, Other Applications
3) By End-User: Hospitals And Ambulatory Surgical Centers, Clinics, Diagnostic And Pathology Labs, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15582&type=discount

Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton, Dickinson and Company (BD), Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, Heska Corporation, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory Lp, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.

Contents of the report:
1. Executive Summary
2. Hematocrit Test Devices Market Report Structure
3. Hematocrit Test Devices Market Trends And Strategies
4. Hematocrit Test Devices Market - Macro Economic Scenario
5. Hematocrit Test Devices Market Size And Growth
…..
27. Hematocrit Test Devices Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.